Research location
Oxon Hill
Maryland, United States
Advertisement
Research activity in Oxon Hill
Maryland, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 102 trials and 102 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Oxon Hill
102 linked trials · page 1 of 3A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusNCT07776509 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightNCT07784270 · 2026-08-20 · 1 site observation
RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusNCT07662109 · 2026-07-06 · 1 site observation
RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388 · 2026-06-22 · 1 site observation
RECRUITING
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeNCT07219602 · 2025-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874 · 2024-08-07 · 1 site observation
COMPLETED
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207 · 2024-04-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 DiabetesNCT06326047 · 2024-03-18 · 1 site observation
COMPLETED
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.NCT05562934 · 2022-11-08 · 1 site observation
COMPLETED
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and OverweightNCT05486065 · 2022-08-08 · 1 site observation
COMPLETED
A Research Study to Compare Two Semaglutide Medicines in People With Type 2 DiabetesNCT05478252 · 2022-08-03 · 1 site observation
COMPLETED
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled AsthmaNCT05251259 · 2022-01-27 · 1 site observation
COMPLETED
Phase 4 COPD and Suboptimal Inspiratory Flow RateNCT05165485 · 2022-01-07 · 1 site observation
COMPLETED
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)NCT05026866 · 2021-08-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 · 2021-08-02 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are OverweightNCT04657003 · 2021-03-29 · 1 site observation
COMPLETED
Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 DiabetesNCT04707469 · 2021-01-15 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450 · 2018-07-13 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusNCT03586830 · 2018-06-26 · 1 site observation
COMPLETED
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03474081 · 2018-03-29 · 1 site observation
COMPLETED
A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DMNCT03090464 · 2017-05-08 · 1 site observation
COMPLETED
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)NCT03057951 · 2017-03-02 · 1 site observation
COMPLETED
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.NCT02849080 · 2016-09-20 · 1 site observation
COMPLETED
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 DiabetesNCT02730377 · 2016-03-28 · 1 site observation
COMPLETED
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.NCT02648204 · 2016-01-06 · 1 site observation
COMPLETED
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 DiabetesNCT02583919 · 2015-09-01 · 1 site observation
COMPLETED
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DMNCT02526524 · 2015-09-01 · 1 site observation
COMPLETED
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinNCT02429258 · 2015-05-01 · 1 site observation
COMPLETED
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT02205528 · 2014-08-18 · 1 site observation
COMPLETED
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes MellitusNCT01991795 · 2014-02-10 · 1 site observation
COMPLETED
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsNCT02019264 · 2014-01-24 · 1 site observation
COMPLETED
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic PatientsNCT01798706 · 2013-06-01 · 1 site observation
COMPLETED
TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 DiabetesNCT01829464 · 2013-05-01 · 1 site observation
TERMINATED
Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 DiabetesNCT01829477 · 2013-04-01 · 1 site observation
TERMINATED
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes MellitusNCT01652729 · 2013-02-01 · 1 site observation
COMPLETED
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose AbnormalitiesNCT01715818 · 2012-12-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes MellitusNCT01699737 · 2012-09-01 · 1 site observation
COMPLETED
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DMNCT01658501 · 2012-07-01 · 1 site observation
COMPLETED
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneNCT01555164 · 2012-06-01 · 1 site observation
COMPLETED
Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 DiabetesNCT01481116 · 2012-01-01 · 1 site observation
TERMINATED
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes MellitusNCT01494987 · 2012-01-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.